About
About Pandion
Leadership
Board of Directors
Advisors
Key Collaborations
Taking Flight Blog
Our Science
TALON™ Platform
What Makes Us Different
Posters & Presentations
Pipeline
Our Pipeline
IL-2 Mutein
PD-1 Agonism
Culture
Our Culture
Community Activities
Investors & News
Careers
Contact
Merck to Acquire Pandion Therapeutics
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases
More
Our TALON™ Platform
is built to create modular protein therapeutics for systemic and local immune regulation
Our pipeline
is built to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases
latest news
February 25, 2021: Merck to Acquire Pandion Therapeutics
February 22, 2021: Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
February 22, 2021: Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting